{
    "id": 18194,
    "fullName": "PARP1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PARP1 positive indicates the presence of the PARP1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 142,
        "geneSymbol": "PARP1",
        "terms": [
            "PARP1",
            "ADPRT",
            "ADPRT 1",
            "ADPRT1",
            "ARTD1",
            "pADPRT-1",
            "PARP",
            "PARP-1",
            "PPOL"
        ]
    },
    "variant": "positive",
    "createDate": "02/17/2016",
    "updateDate": "01/03/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12816,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of AG-14361 to Hycamtin (topotecan) increased sensitivity 3-fold in PARP1-positive cells in culture, demonstrating growth inhibition and cell death (PMID: 16322308).",
            "molecularProfile": {
                "id": 18523,
                "profileName": "PARP1 positive"
            },
            "therapy": {
                "id": 6680,
                "therapyName": "AG-14361 + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10749,
                    "pubMedId": 16322308,
                    "title": "The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16322308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4558,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BSI-401 and Eloxatin (oxaliplatin) synergized to inhibit tumor growth in human PARP-1-expressing pancreatic cancer cell line xenograft models, and resulted in increased median survival compared to either agent alone (PMID: 19808866).",
            "molecularProfile": {
                "id": 18523,
                "profileName": "PARP1 positive"
            },
            "therapy": {
                "id": 3540,
                "therapyName": "BSI-401 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4607,
                    "pubMedId": 19808866,
                    "title": "Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19808866"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4557,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BSI-401 inhibited growth of several PARP1-expressing human pancreatic cancer cell lines in culture and in xenograft models (PMID: 19808866).",
            "molecularProfile": {
                "id": 18523,
                "profileName": "PARP1 positive"
            },
            "therapy": {
                "id": 3539,
                "therapyName": "BSI-401",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4607,
                    "pubMedId": 19808866,
                    "title": "Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19808866"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14543,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells of patients with advanced solid tumors, and resulted in partial response in 4.9% (2/41) and stable disease in 31.7% (13/41) of the patients (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 724,
                "therapyName": "E7449",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11738,
                    "pubMedId": null,
                    "title": "First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_224139.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10838,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells of patients with advanced solid tumors, and resulted in a partial response in 4% (1/25) and stable disease in 20% (5/25) of the patients (J Clin Oncol 32, 2014, suppl; abstr e19531).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 724,
                "therapyName": "E7449",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8865,
                    "pubMedId": null,
                    "title": "Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.",
                    "url": "http://meetinglibrary.asco.org/content/131248-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10829,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of CEP-9722 and Temodar (temozolomide) inhibited Parp activity and resulted in a partial response in 4% (1/26) of patients with advanced solid tumors (PMID: 24880570).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 5654,
                "therapyName": "CEP-9722 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2482,
                    "pubMedId": 24880570,
                    "title": "Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24880570"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14544,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells and resulted in partial response in 40% (2/5) of the patients with ovarian cancer (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 724,
                "therapyName": "E7449",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11738,
                    "pubMedId": null,
                    "title": "First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_224139.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10839,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INO-1001 inhibited Parp activity and sensitized transformed cells to radiation toxicity in culture (PMID: 15036647).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 5657,
                "therapyName": "INO-1001 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3295,
                    "pubMedId": 15036647,
                    "title": "Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15036647"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10833,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, E7016 demonstrated safety and resulted in preliminary efficacy, including Parp inhibition and increased DNA damage in peripheral blood mononuclear cells of patients with advanced solid tumors (Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B185).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 2539,
                "therapyName": "E7016",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8861,
                    "pubMedId": null,
                    "title": "Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.",
                    "url": "http://mct.aacrjournals.org/content/10/11_Supplement/B185.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10830,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of CEP-9722 and Temodar (temozolomide) inhibited Parp activity and resulted in partial response in a patient with melanoma (PMID: 24880570).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 5654,
                "therapyName": "CEP-9722 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2482,
                    "pubMedId": 24880570,
                    "title": "Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24880570"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14545,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, E7449 treatment inhibited Parp activity in peripheral blood mononuclear cells and resulted in stable disease for more than 24 weeks in 7 patients with pancreatic cancer (J Clin Oncol 36, 2018 (suppl; abstr 2505); abstr e19531; NCT01618136).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 724,
                "therapyName": "E7449",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11738,
                    "pubMedId": null,
                    "title": "First-in-human phase 1 study of the PARP/tankyrase inhibitor 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and validation of a novel drug response predictor (DRP) mRNA biomarker.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_224139.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10832,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of E7016 and Temodar (temozolomide) demonstrated safety and resulted in preliminary efficacy, including Parp inhibition and increased DNA damage in peripheral blood mononuclear cells of patients with advanced solid tumors (Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B185).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 5655,
                "therapyName": "E7016 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8861,
                    "pubMedId": null,
                    "title": "Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide (TMZ) in patients with advanced solid tumors.",
                    "url": "http://mct.aacrjournals.org/content/10/11_Supplement/B185.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18523,
            "profileName": "PARP1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27810,
            "profileName": "PARP1 pos PARP2 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}